// App-Quantinova.ai

: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Researchers

Presenter

  • Sammicheli Stefano

Principal Investigators

  • Camille Grandclement

  • Valentina Labanca

  • Stefania De Angelis

  • Carole Estoppey

  • Myriam Chimen

  • Blandine Pouleau

  • Perrine Suere

  • Emilie Nallet

  • ANKITA SRIVASTAVA

  • Eric J. Feldman

  • Igor Proscurshim

  • Cyril Konto

  • Eugene Zhukovsky

  • Mario Perro

Medical Centers

  • Ichnos Sciences, New York

  • Ichnos Sciences, Epalinges, Switzerland

  • Ichnos Sciences Biotherapeutics SA, Lausanne, Switzerland

Locations

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Acute myelocytic leukemia

  • Hematologic and solid malignancies

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Natural Killer cells

  • Peripheral blood mononuclear cell

  • Red Blood Cells

  • T-cell receptor

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved